Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data Transcript [Seeking Alpha]
Corbus Pharmaceuticals (NASDAQ:CRBP) had its price target lowered by analysts at Royal Bank Of Canada from $55.00 to $53.00. They now have an "outperform" rating on the stock.
Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
Corbus Pharmaceuticals: Downgrade To Hold Due To Narrow Focus Window [Seeking Alpha]